LeMaitre Vascular Inc (LMAT) CEO George W. Lemaitre Sells 30,000 Shares

LeMaitre Vascular Inc (NASDAQ:LMAT) CEO George W. Lemaitre sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 23rd. The shares were sold at an average price of $33.05, for a total value of $991,500.00. Following the completion of the sale, the chief executive officer now directly owns 3,157,009 shares in the company, valued at $104,339,147.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of NASDAQ:LMAT traded up $0.04 during trading on Thursday, reaching $33.09. The stock had a trading volume of 1,421 shares, compared to its average volume of 244,327. The firm has a market capitalization of $634.03 million, a PE ratio of 37.92, a P/E/G ratio of 2.02 and a beta of 0.57. LeMaitre Vascular Inc has a 1-year low of $25.05 and a 1-year high of $41.28.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Wednesday, April 25th. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.21 by ($0.02). The firm had revenue of $25.99 million during the quarter, compared to analyst estimates of $26.42 million. LeMaitre Vascular had a return on equity of 16.66% and a net margin of 17.34%. The business’s revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.16 earnings per share. analysts forecast that LeMaitre Vascular Inc will post 1.08 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 7th. Stockholders of record on Tuesday, May 22nd will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend is Monday, May 21st. LeMaitre Vascular’s dividend payout ratio is presently 32.56%.

A number of institutional investors have recently made changes to their positions in the stock. Advisor Group Inc. lifted its position in LeMaitre Vascular by 28.3% during the fourth quarter. Advisor Group Inc. now owns 7,033 shares of the medical instruments supplier’s stock worth $223,000 after buying an additional 1,550 shares in the last quarter. Algert Global LLC lifted its position in LeMaitre Vascular by 2.0% during the fourth quarter. Algert Global LLC now owns 86,858 shares of the medical instruments supplier’s stock worth $2,766,000 after buying an additional 1,673 shares in the last quarter. Swiss National Bank lifted its position in LeMaitre Vascular by 6.8% during the first quarter. Swiss National Bank now owns 26,600 shares of the medical instruments supplier’s stock worth $964,000 after buying an additional 1,700 shares in the last quarter. Sapphire Star Partners LP lifted its position in LeMaitre Vascular by 18.1% during the first quarter. Sapphire Star Partners LP now owns 12,431 shares of the medical instruments supplier’s stock worth $450,000 after buying an additional 1,906 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in LeMaitre Vascular by 3.7% during the fourth quarter. Rhumbline Advisers now owns 60,673 shares of the medical instruments supplier’s stock worth $1,932,000 after buying an additional 2,138 shares in the last quarter. Hedge funds and other institutional investors own 72.74% of the company’s stock.

Several brokerages have commented on LMAT. Stifel Nicolaus lowered LeMaitre Vascular from a “buy” rating to a “hold” rating and dropped their price objective for the company from $40.00 to $34.00 in a report on Thursday, April 26th. ValuEngine raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Wednesday, April 4th. BidaskClub raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, March 9th. Canaccord Genuity reaffirmed a “hold” rating and issued a $33.00 price target on shares of LeMaitre Vascular in a research note on Friday, February 23rd. Finally, Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Wednesday, February 28th. Six investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $35.33.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply